Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma

Figure 1 Kaplan-Meier analysis. A: Hepatocellular carcinoma (HCC) recurrence/occurrence after direct-acting antiviral (DAA) treatment of patients with (solid line) and without (dotted line) a history of HCC; B: Kaplan-Meier analysis of HCC events after DAA treatment in patients with 1 (solid line), 2 (dotted line), and ≥ 3 (dashed line) HCC events before DAA treatment. Numbers in parenthesis = 95% confidence interval. NR: Not reached; RFS: Recurrence-free survival; CI: Confidence interval; HCC: Hepatocellular carcinoma.

Figure 2 Median recurrence-free survival in patients with hepatocellular carcinoma recurrence before and after direct-acting antivirals treatment. A: Kaplan-Meier analysis of hepatocellular carcinoma (HCC) recurrence before (solid line) and after (dotted line) direct-acting antiviral (DAA) treatment in patients with a history of HCC; B: Schema of HCC events. Solid triangle = one event. Black bar = period in days. Numbers in parenthesis = 95% confidence interval. RFS: Recurrence-free survival; HCC: Hepatocellular carcinoma; DAA: Direct-acting antiviral.